BFEC
PHAS

Benjamin F. Edwards & Company’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Benjamin F. Edwards & Company’s Portfolio PHAS Stock Details PHAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1,000
Closed -$6K – 1930
2019
Q4 		$6K Buy
+1,000
New +$4.12K ﹤0.01% 1583

Other funds holding PHAS

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Benjamin F. Edwards & Company's PHAS Position: Q1 2020 in Review

Benjamin F. Edwards & Company sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q1 2020, closing a stake of 1,000 shares — an estimated $6K sold.

Benjamin F. Edwards & Company first reported a position in PHAS in Q4 2019 and held it in 1 quarter. The position peaked at $6K in Q4 2019. 50 funds tracked by Wall St. Rank hold PHAS as of Q1 2020.

  • Benjamin F. Edwards & Company reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Benjamin F. Edwards & Company sold 1,000 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q1 2020, an estimated $6K.
  • Benjamin F. Edwards & Company first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q4 2019 and held it in 1 quarter.
  • Benjamin F. Edwards & Company's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $6K in Q4 2019.
  • 50 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q1 2020.

Based on Benjamin F. Edwards & Company's 13F filing for Q1 2020, filed 7 May 2020.